ReviewFrontiers in immunology2026
Membrane-modified mesoporous silica nanoparticles guided by tumor immunomodulatory regulation for anti-tumor strategies.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bioinspired and Biomimetic Nanocarriers: Advances in Exosomes and Cell-Membrane-Coated Systems for Therapeutic Applications.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The effective treatment of cancer remains challenging due to the highly immunosuppressive and complex tumor immune microenvironment (TIME). Mesoporous silica nanoparticles (MSNs), known for their tunable pore structures and high drug-loading capacity, have been extensively employed in cancer diagnosis and therapy. To combat the development of cancer, emerging studies on cell membrane-coated MSNs (CM-MSNs) reveal that these systems integrate the intrinsic features of MSNs with unique biological functions inherited from source cells-such as immune evasion, tumor targeting, and prolonged circulation-thereby addressing key limitations of bare nanoparticles, including poor targeting efficiency and uncontrolled drug release. As a biomimetic drug delivery platform, they enhance tumor-targeted accumulation through membrane-mediated homing and exert profound immunomodulatory effects within TIME. This review systematically summarizes recent advances in MSNs coated with membranes derived from diverse cellular sources, including innate and adaptive immune cells, blood cells, cancer cells, and engineered hybrid cells, with a particular focus on their roles in regulating the tumor-immune interface. We further discuss the prospects and challenges for the clinical translation of CM-MSNs. Collectively, these developments inspire innovative designs for biomimetic nanoplatforms and open new avenues for optimizing cancer immunotherapy, both via precise manipulation of cellular interactions at the immune interface.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.